Is Progyny Inc (PGNY) overvalued? · P/E 38, rev $298.4M
Progyny Inc (PGNY) is a healthcare plans company listed on US.
This page asks whether Progyny Inc (PGNY) looks expensive on cached numbers — not a short thesis.
Latest reported PGNY revenue for 2024-12-31 was $298.4M. Net income was $54.3M. Revenue was up 4.1% from 2024-09-30 to 2024-12-31. PGNY currently screens at market cap $1.84B and trailing P/E 37.6.
PGNY currently screens at market cap $1.84B and trailing P/E 37.6. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PGNY 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PGNY stock page for the full model, not this heading.
Not investment advice.